Pfizer: new positive study data in Covid
(CercleFinance.com) - On Saturday Pfizer and BioNTech announced positive data from the Phase 2/3 trial evaluating the safety, tolerability and immunogenicity of two Omicron-adapted Covid-19 vaccine candidates: one monovalent and one bivalent.
The monovalent omicron-adapted candidate administered as the fourth booster dose resulted in a 13.5- and 19.6-fold increase in neutralising geometric titers compared to Omicron BA.1 at doses of 30 μg and 60 μg.
The bivalent candidate (a combination of Pfizer-BioNTech's vaccine and a candidate vaccine targeting the peak protein of the Omicron BA.1 variant of concern) showed a 9.1- and 10.9-fold increase over Omicron.
Copyright (c) 2022 CercleFinance.com. All rights reserved.